Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP

William F. Goeckeler, L. Kris Stoneburner, Leela P. Kasi, Frank V. Fossella, Diana R. Price, William A. Fordyce

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

153Sm-EDTMP is currently undergoing clinical evaluation as a radiotherapeutic agent for the relief of pain associated with cancer metastatic to bone. These clinical studies have demonstrated biodistributions similar to those seen earlier in animals, namely, rapid clearance from blood, selective uptake in bone and in particular metastatic bone lesions. The radioactivity not deposited in bone is cleared through the kidneys into the urine. In this study, urine samples collected from 9 patients injected with 153Sm-EDTMP underwent complexation analysis via Pharmacia SP-Sephadex® C25 cation exchange chromatography. The results showed 96.9 ± 1.7% of the radioactivity in the urine to be present as a complex of 153Sm. An HPLC method was developed and it was demonstrated that different complexes of 153Sm could be separated. A non-radioactive analytical standard of the Sm-EDTMP chelate was synthesized, characterized and shown to have the same HPLC retention profile as the 153Sm-EDTMP drug product. HPLC analysis was performed on six urine samples and in each case a single radioactivity peak with an elution profile the same as that of a 153Sm-EDTMP standard was observed. These results indicate that the 153Sm-EDTMP chelate is excreted intact in the urine of patients.

Original languageEnglish (US)
Pages (from-to)657-661
Number of pages5
JournalNuclear Medicine and Biology
Volume20
Issue number5
DOIs
StatePublished - Jul 1993

Fingerprint

Bone Neoplasms
Urine
Radioactivity
Bone and Bones
High Pressure Liquid Chromatography
samarium ethylenediaminetetramethylenephosphonate
Cations
Chromatography
Kidney
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. / Goeckeler, William F.; Stoneburner, L. Kris; Kasi, Leela P.; Fossella, Frank V.; Price, Diana R.; Fordyce, William A.

In: Nuclear Medicine and Biology, Vol. 20, No. 5, 07.1993, p. 657-661.

Research output: Contribution to journalArticle

Goeckeler, William F. ; Stoneburner, L. Kris ; Kasi, Leela P. ; Fossella, Frank V. ; Price, Diana R. ; Fordyce, William A. / Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. In: Nuclear Medicine and Biology. 1993 ; Vol. 20, No. 5. pp. 657-661.
@article{436afb664b26471aa040db8d34b97f83,
title = "Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP",
abstract = "153Sm-EDTMP is currently undergoing clinical evaluation as a radiotherapeutic agent for the relief of pain associated with cancer metastatic to bone. These clinical studies have demonstrated biodistributions similar to those seen earlier in animals, namely, rapid clearance from blood, selective uptake in bone and in particular metastatic bone lesions. The radioactivity not deposited in bone is cleared through the kidneys into the urine. In this study, urine samples collected from 9 patients injected with 153Sm-EDTMP underwent complexation analysis via Pharmacia SP-Sephadex{\circledR} C25 cation exchange chromatography. The results showed 96.9 ± 1.7{\%} of the radioactivity in the urine to be present as a complex of 153Sm. An HPLC method was developed and it was demonstrated that different complexes of 153Sm could be separated. A non-radioactive analytical standard of the Sm-EDTMP chelate was synthesized, characterized and shown to have the same HPLC retention profile as the 153Sm-EDTMP drug product. HPLC analysis was performed on six urine samples and in each case a single radioactivity peak with an elution profile the same as that of a 153Sm-EDTMP standard was observed. These results indicate that the 153Sm-EDTMP chelate is excreted intact in the urine of patients.",
author = "Goeckeler, {William F.} and Stoneburner, {L. Kris} and Kasi, {Leela P.} and Fossella, {Frank V.} and Price, {Diana R.} and Fordyce, {William A.}",
year = "1993",
month = "7",
doi = "10.1016/0969-8051(93)90036-T",
language = "English (US)",
volume = "20",
pages = "657--661",
journal = "International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP

AU - Goeckeler, William F.

AU - Stoneburner, L. Kris

AU - Kasi, Leela P.

AU - Fossella, Frank V.

AU - Price, Diana R.

AU - Fordyce, William A.

PY - 1993/7

Y1 - 1993/7

N2 - 153Sm-EDTMP is currently undergoing clinical evaluation as a radiotherapeutic agent for the relief of pain associated with cancer metastatic to bone. These clinical studies have demonstrated biodistributions similar to those seen earlier in animals, namely, rapid clearance from blood, selective uptake in bone and in particular metastatic bone lesions. The radioactivity not deposited in bone is cleared through the kidneys into the urine. In this study, urine samples collected from 9 patients injected with 153Sm-EDTMP underwent complexation analysis via Pharmacia SP-Sephadex® C25 cation exchange chromatography. The results showed 96.9 ± 1.7% of the radioactivity in the urine to be present as a complex of 153Sm. An HPLC method was developed and it was demonstrated that different complexes of 153Sm could be separated. A non-radioactive analytical standard of the Sm-EDTMP chelate was synthesized, characterized and shown to have the same HPLC retention profile as the 153Sm-EDTMP drug product. HPLC analysis was performed on six urine samples and in each case a single radioactivity peak with an elution profile the same as that of a 153Sm-EDTMP standard was observed. These results indicate that the 153Sm-EDTMP chelate is excreted intact in the urine of patients.

AB - 153Sm-EDTMP is currently undergoing clinical evaluation as a radiotherapeutic agent for the relief of pain associated with cancer metastatic to bone. These clinical studies have demonstrated biodistributions similar to those seen earlier in animals, namely, rapid clearance from blood, selective uptake in bone and in particular metastatic bone lesions. The radioactivity not deposited in bone is cleared through the kidneys into the urine. In this study, urine samples collected from 9 patients injected with 153Sm-EDTMP underwent complexation analysis via Pharmacia SP-Sephadex® C25 cation exchange chromatography. The results showed 96.9 ± 1.7% of the radioactivity in the urine to be present as a complex of 153Sm. An HPLC method was developed and it was demonstrated that different complexes of 153Sm could be separated. A non-radioactive analytical standard of the Sm-EDTMP chelate was synthesized, characterized and shown to have the same HPLC retention profile as the 153Sm-EDTMP drug product. HPLC analysis was performed on six urine samples and in each case a single radioactivity peak with an elution profile the same as that of a 153Sm-EDTMP standard was observed. These results indicate that the 153Sm-EDTMP chelate is excreted intact in the urine of patients.

UR - http://www.scopus.com/inward/record.url?scp=0027193257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027193257&partnerID=8YFLogxK

U2 - 10.1016/0969-8051(93)90036-T

DO - 10.1016/0969-8051(93)90036-T

M3 - Article

C2 - 8358352

AN - SCOPUS:0027193257

VL - 20

SP - 657

EP - 661

JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

SN - 0969-8051

IS - 5

ER -